Comparison of 18F-AlF-NOTA-FAPI and 18F-FDG Imaging in a Patient With Gastric Signet-Ring Cell Carcinoma. (November 2021)

• Record Type: Journal Article
• Authors: Guo, Yue-Hong; Yang, Min-Fu
• Is Part Of: Clinical nuclear medicine. Volume 46:Number 11(2021)
• Publication Date: 2021-11
• Subjects: 18F-AlF-NOTA-FAPI -- 18F-FDG -- gastric signet-ring cell carcinoma; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003742
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Several case reports have shown fibroblast activation protein inhibitor (FAPI) imaging to be superior to 18 F-FDG imaging in the delineation of primary gastric signet-ring cell carcinoma lesions. In this case, 18 F-AlF-NOTA-FAPI PET/CT showed more metastatic lesions that had more increased activity than 18 F-FDG PET/CT. However, neither 18 F-AlF-NOTA-FAPI nor 18 F-FDG imaging revealed any abnormal uptake in the primary gastric lesion, which was subsequently demonstrated to be the primary lesion by pathology.